Prostate tumor OVerexpressed-1 (PTOV1) down-regulates HES1 and HEY1 notch targets genes and promotes prostate cancer progression

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Alaña, Lide ^a   Sesé, Marta ^a   Cánovas, Verónica ^a   Punyal, Yolanda ^a   Fernández, Yolanda ^a,b   Abasolo, Ibane ^a,b   De Torres, Inés ^c   Ruiz, Cristina ^d   Espinosa, Lluís ^d   Bigas, Anna ^d   y Cajal, Santiago R ^c   Fernández, Pedro L ^e   Serras, Florenci ^f   Corominas, Montserrat ^f   Thomson, Timothy M ^b,g   Paciucci, Rosanna ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

HES1; HEY1; Notch signaling; prostate cancer progression; PTOV1

Indexed keywords

ADAPTOR PROTEIN; LENTIVIRUS VECTOR; PROSTATE TUMOR OVEREXPRESSED 1 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR HEY 1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CELL CYCLE PROTEIN; HES1 PROTEIN, HUMAN; HEY1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; NOTCH RECEPTOR; PTOV1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER TISSUE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DELETION MUTANT; DISEASE COURSE; DOWN REGULATION; DROSOPHILA MELANOGASTER; FORELIMB; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LUCIFERASE ASSAY; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR GENE; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DROSOPHILA MELANOGASTER; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HOMEODOMAIN PROTEINS; HUMANS; MALE; MICE; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84897475336     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-74     Document Type: Article

References (73)

1. Benedit P, Paciucci R, Thomson TM, Valeri M, Nadal M, Caceres C, de Torres I, Estivill X, Lozano JJ, Morote J, Reventos J. PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. Oncogene 2001, 20(12):1455-1464. 10.1038/sj.onc.1204233, 11313889.
2. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF, Hampton GM. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001, 61(16):5974-5978.
3. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004, 101(3):811-816. 10.1073/pnas.0304146101, 321763, 14711987.
4. Santamaria A, Fernandez PL, Farre X, Benedit P, Reventos J, Morote J, Paciucci R, Thomson TM. PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. Am J Pathol 2003, 162(3):897-905. 10.1016/S0002-9440(10)63885-0, 1868092, 12598323.
5. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, Poggio T, Gerald W, Loda M, Lander ES, Golub TR. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001, 98(26):15149-15154. 10.1073/pnas.211566398, 64998, 11742071.
6. Fernandez S, Mosquera JL, Alana L, Sanchez-Pla A, Morote J, Ramon YCS, Reventos J, de Torres I, Paciucci R. PTOV1 is overexpressed in human high-grade malignant tumors. Virchows Arch 2011, 458(3):323-330. 10.1007/s00428-010-1018-1, 21181414.
7. Mazzucchelli R, Scarpelli M, Barbisan F, Santinelli A, Lopez-Beltran A, Cheng L, Montironi R. Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking (AAH) to adenocarcinoma. Cell Oncol (Dordrecht) 2013, 36:37-42.
8. Morote J, Fernandez S, Alana L, Iglesias C, Planas J, Reventos J, Ramon YCS, Paciucci R, de Torres IM. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Clin Cancer Res 2008, 14(9):2617-2622. 10.1158/1078-0432.CCR-07-4987, 18451224.
9. Mittler G, Stuhler T, Santolin L, Uhlmann T, Kremmer E, Lottspeich F, Berti L, Meisterernst M. A novel docking site on Mediator is critical for activation by VP16 in mammalian cells. EMBO J 2003, 22(24):6494-6504. 10.1093/emboj/cdg619, 291814, 14657022.
10. Yang F, DeBeaumont R, Zhou S, Naar AM. The activator-recruited cofactor/Mediator coactivator subunit ARC92 is a functionally important target of the VP16 transcriptional activator. Proc Natl Acad Sci U S A 2004, 101(8):2339-2344. 10.1073/pnas.0308676100, 356952, 14983011.
11. Vojnic E, Mourao A, Seizl M, Simon B, Wenzeck L, Lariviere L, Baumli S, Baumgart K, Meisterernst M, Sattler M, Cramer P. Structure and VP16 binding of the Mediator Med25 activator interaction domain. Nat Struct Mol Biol 2011, 18(4):404-409. 10.1038/nsmb.1997, 21378965.
12. Milbradt AG, Kulkarni M, Yi T, Takeuchi K, Sun ZY, Luna RE, Selenko P, Naar AM, Wagner G. Structure of the VP16 transactivator target in the Mediator. Nat Struct Mol Biol 2011, 18(4):410-415. 10.1038/nsmb.1999, 3076674, 21378963.
13. Bontems F, Verger A, Dewitte F, Lens Z, Baert JL, Ferreira E, de Launoit Y, Sizun C, Guittet E, Villeret V, Monte D. NMR structure of the human Mediator MED25 ACID domain. J Struct Biol 2010, 174(1):245-251.
14. Youn HS, Park UH, Kim EJ, Um SJ. PTOV1 antagonizes MED25 in RAR transcriptional activation. Biochem Biophys Res Commun 2011, 404(1):239-244. 10.1016/j.bbrc.2010.11.100, 21110951.
15. Youn H, Kim EJ, Um SJ. Zyxin cooperates with PTOV1 to confer retinoic acid resistance by repressing RAR activity. Cancer Lett 2013, 331:192-199. 10.1016/j.canlet.2012.12.019, 23321499.
16. Santamaria A, Castellanos E, Gomez V, Benedit P, Renau-Piqueras J, Morote J, Reventos J, Thomson TM, Paciucci R. PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. Mol Cell Biol 2005, 25(5):1900-1911. 10.1128/MCB.25.5.1900-1911.2005, 549350, 15713644.
17. Benzinger A, Muster N, Koch HB, Yates JR, Hermeking H. Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics 2005, 4(6):785-795. 10.1074/mcp.M500021-MCP200, 15778465.
18. Hard RL, Liu J, Shen J, Zhou P, Pei D. HDAC6 and Ubp-M BUZ domains recognize specific C-terminal sequences of proteins. Biochemistry 2010, 49(50):10737-10746. 10.1021/bi101014s, 3005221, 21090589.
19. Marques N, Sese M, Canovas V, Valente F, Bermudo R, de Torres I, Fernandez Y, Abasolo I, Fernandez PL, Contreras H, Castellon E, Celia-Terrassa T, Mendez R, Ramon YCS, Thomson TM, Paciucci R. Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1. Oncogene 2014, 33:1124-1134. 10.1038/onc.2013.51, 23455324.
20. Lee HK, Park UH, Kim EJ, Um SJ. MED25 is distinct from TRAP220/MED1 in cooperating with CBP for retinoid receptor activation. EMBO J 2007, 26(15):3545-3557. 10.1038/sj.emboj.7601797, 1949011, 17641689.
21. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science 1999, 284(5415):770-776. 10.1126/science.284.5415.770, 10221902.
22. Brou C, Logeat F, Gupta N, Bessia C, LeBail O, Doedens JR, Cumano A, Roux P, Black RA, Israel A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 2000, 5(2):207-216. 10.1016/S1097-2765(00)80417-7, 10882063.
23. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol 2000, 228(2):151-165. 10.1006/dbio.2000.9960, 11112321.
24. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature 1995, 377(6547):355-358. 10.1038/377355a0, 7566092.
25. Iso T, Sartorelli V, Poizat C, Iezzi S, Wu HY, Chung G, Kedes L, Hamamori Y. HERP, a novel heterodimer partner of HES/E(spl) in Notch signaling. Mol Cell Biol 2001, 21(17):6080-6089. 10.1128/MCB.21.17.6080-6089.2001, 87325, 11486045.
26. Lai EC. Keeping a good pathway down: transcriptional repression of Notch pathway target genes by CSL proteins. EMBO Rep 2002, 3(9):840-845. 10.1093/embo-reports/kvf170, 1084223, 12223465.
27. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66(4):649-661. 10.1016/0092-8674(91)90111-B, 1831692.
28. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ, Herlyn M, Liu ZJ. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 2005, 115(11):3166-3176. 10.1172/JCI25001, 1257536, 16239965.
29. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435(7044):959-963. 10.1038/nature03659, 15959515.
30. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, Haeno H, Buonamici S, van De Walle I, Cathelin S, Trimarchi T, Araldi E, Liu C, Ibrahim S, Beran M, Zavadil J, Efstratiadis A, Taghon T, Michor F, Levine RL, Aifantis I. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011, 473(7346):230-233. 10.1038/nature09999, 3093658, 21562564.
31. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003, 33(3):416-421. 10.1038/ng1099, 12590261.
32. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011, 11(5):338-351. 10.1038/nrc3035, 21508972.
33. Leong KG, Gao WQ. The Notch pathway in prostate development and cancer. Differentiation 2008, 76(6):699-716. 10.1111/j.1432-0436.2008.00288.x, 18565101.
34. Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE. Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression. J Cell Biochem 2009, 107(5):992-1001. 10.1002/jcb.22199, 19479935.
35. Wang XD, Leow CC, Zha J, Tang Z, Modrusan Z, Radtke F, Aguet M, de Sauvage FJ, Gao WQ. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006, 290(1):66-80. 10.1016/j.ydbio.2005.11.009, 16360140.
36. Shou J, Ross S, Koeppen H, de Sauvage FJ, Gao WQ. Dynamics of notch expression during murine prostate development and tumorigenesis. Cancer Res 2001, 61(19):7291-7297.
37. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004, 64(19):6854-6857. 10.1158/0008-5472.CAN-04-2500, 15466172.
38. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J, Petrylak DP, Benson MC, Silva JM, Cordon-Cardo C. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012, 22(3):373-388. 10.1016/j.ccr.2012.07.016, 22975379.
39. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, Sarkar FH. Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways. J Cell Biochem 2010, 109(4):726-736.
40. Kung AL, Rebel VI, Bronson RT, Chng LE, Sieff CA, Livingston DM, Yao TP. Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. Genes Dev 2000, 14(3):272-277. 316359, 10673499.
41. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM. Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A 2002, 99(23):14789-14794. 10.1073/pnas.232568499, 137497, 12397173.
42. Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, Wang L, Yu C, Rizzardi T, Cheng L, Zhang J, Schmechel SC, Cheville JC, van Deursen J, Tindall DJ, Huang H. CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy. Cancer Res 2014,
43. Gong AY, Eischeid AN, Xiao J, Zhao J, Chen D, Wang ZY, Young CY, Chen XM. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer 2012, 12:492. 10.1186/1471-2407-12-492, 3519561, 23095762.
44. Santer FR, Hoschele PP, Oh SJ, Erb HH, Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA, Culig Z. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 2011, 10(9):1644-1655. 10.1158/1535-7163.MCT-11-0182, 21709130.
45. Comuzzi B, Nemes C, Schmidt S, Jasarevic Z, Lodde M, Pycha A, Bartsch G, Offner F, Culig Z, Hobisch A. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004, 204(2):159-166. 10.1002/path.1609, 15378487.
46. Wang XD, Shou J, Wong P, French DM, Gao WQ. Notch1-expressing cells are indispensable for prostatic branching morphogenesis during development and re-growth following castration and androgen replacement. J Biol Chem 2004, 279(23):24733-24744. 10.1074/jbc.M401602200, 15028713.
47. Robinson DR, Zylstra CR, Williams BO. Wnt signaling and prostate cancer. Curr Drug Targets 2008, 9(7):571-580.
48. Geling A, Steiner H, Willem M, Bally-Cuif L, Haass C. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep 2002, 3(7):688-694. 10.1093/embo-reports/kvf124, 1084181, 12101103.
49. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet 2000, 26(4):484-489. 10.1038/82644, 11101851.
50. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 1990, 265(28):17174-17179.
51. Oswald F, Kostezka U, Astrahantseff K, Bourteele S, Dillinger K, Zechner U, Ludwig L, Wilda M, Hameister H, Knochel W, Liptay S, Schmid RM. SHARP is a novel component of the Notch/RBP-Jkappa signalling pathway. EMBO J 2002, 21(20):5417-5426. 10.1093/emboj/cdf549, 129081, 12374742.
52. Poulson DF. Chromosomal Deficiencies and the Embryonic Development of Drosophila Melanogaster. Proc Natl Acad Sci U S A 1937, 23(3):133-137. 10.1073/pnas.23.3.133, 1076884, 16588136.
53. de Celis JF, Garcia-Bellido A. Modifications of the notch function by Abruptex mutations in Drosophila melanogaster. Genetics 1994, 136(1):183-194. 1205770, 8138156.
54. Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development 1993, 118(2):401-415.
55. Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, Lambertini C, Neel V, Dummer R, Wagner EF, Dotto GP. EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol 2008, 10(8):902-911. 10.1038/ncb1750, 2747621, 18604200.
56. Hong SH, Privalsky ML. The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export. Mol Cell Biol 2000, 20(17):6612-6625. 10.1128/MCB.20.17.6612-6625.2000, 86146, 10938135.
57. Kao HY, Ordentlich P, Koyano-Nakagawa N, Tang Z, Downes M, Kintner CR, Evans RM, Kadesch T. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998, 12(15):2269-2277. 10.1101/gad.12.15.2269, 317043, 9694793.
58. Fernandez-Majada V, Aguilera C, Villanueva A, Vilardell F, Robert-Moreno A, Aytes A, Real FX, Capella G, Mayo MW, Espinosa L, Bigas A. Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc Natl Acad Sci U S A 2007, 104(1):276-281. 10.1073/pnas.0606476104, 1765449, 17190815.
59. Kinoshita M, Nakagawa T, Shimizu A, Katsuoka Y. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate. Int J Urol 2005, 12(4):390-397. 10.1111/j.1442-2042.2005.01093.x, 15948728.
60. Zhou S, Fujimuro M, Hsieh JJ, Chen L, Miyamoto A, Weinmaster G, Hayward SD. SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC To facilitate NotchIC function. Mol Cell Biol 2000, 20(7):2400-2410. 10.1128/MCB.20.7.2400-2410.2000, 85419, 10713164.
61. Feng Y, Bommer GT, Zhai Y, Akyol A, Hinoi T, Winer I, Lin HV, Cadigan KM, Cho KR, Fearon ER. Drosophila split ends homologue SHARP functions as a positive regulator of Wnt/beta-catenin/T-cell factor signaling in neoplastic transformation. Cancer Res 2007, 67(2):482-491. 10.1158/0008-5472.CAN-06-2314, 17234755.
62. Shi Y, Downes M, Xie W, Kao HY, Ordentlich P, Tsai CC, Hon M, Evans RM. Sharp, an inducible cofactor that integrates nuclear receptor repression and activation. Genes Dev 2001, 15(9):1140-1151. 10.1101/gad.871201, 312688, 11331609.
63. Conlon RA, Reaume AG, Rossant J. Notch1 is required for the coordinate segmentation of somites. Development 1995, 121(5):1533-1545.
64. Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T. Notch1 is essential for postimplantation development in mice. Genes Dev 1994, 8(6):707-719. 10.1101/gad.8.6.707, 7926761.
65. de la Pompa JL, Wakeham A, Correia KM, Samper E, Brown S, Aguilera RJ, Nakano T, Honjo T, Mak TW, Rossant J, Conlon RA. Conservation of the Notch signalling pathway in mammalian neurogenesis. Development 1997, 124(6):1139-1148.
66. Nakayama K, Satoh T, Igari A, Kageyama R, Nishida E. FGF induces oscillations of Hes1 expression and Ras/ERK activation. Curr Biol 2008, 18(8):R332-R334. 10.1016/j.cub.2008.03.013, 18430630.
67. Yoshiura S, Ohtsuka T, Takenaka Y, Nagahara H, Yoshikawa K, Kageyama R. Ultradian oscillations of Stat, Smad, and Hes1 expression in response to serum. Proc Natl Acad Sci U S A 2007, 104(27):11292-11297. 10.1073/pnas.0701837104, 1899192, 17592117.
68. Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, van Galen M, van Dam H, van Ommen GJ, den Dunnen JT, Zantema A, t Hoen PA. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res 2010, 38(16):5396-5408. 10.1093/nar/gkq184, 2938195, 20435671.
69. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003, 63(22):7638-7640.
70. Zhong J, Ding L, Bohrer LR, Pan Y, Liu P, Zhang J, Sebo TJ, Karnes RJ, Tindall DJ, van Deursen J, Huang H. P300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res 2014,
71. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression and late steps of malignant transformation. Genes Dev 2002, 16(17):2252-2263. 10.1101/gad.988902, 186663, 12208848.
72. Hu B, Castillo E, Harewood L, Ostano P, Reymond A, Dummer R, Raffoul W, Hoetzenecker W, Hofbauer GF, Dotto GP. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 2012, 149(6):1207-1220. 10.1016/j.cell.2012.03.048, 3578441, 22682244.
73. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen LS, Jay G. Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci U S A 1994, 91(25):11874-11878. 10.1073/pnas.91.25.11874, 45338, 7991549.